Janssen inks $150m deal for blood cancer drug
pharmafile | December 12, 2011 | News story | Research and Development, Sales and Marketing | Janssen, Pharmacyclics
Janssen biotech has signed a licensing deal with Pharmacyclics for its investigational blood cancer drug.
The firm has paid $150 million up front for Pharmacyclics’s PCI-32765, an oral, first-in-class Bruton’s tyrosine kinase inhibitor being developed for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and multiple myeloma.
Pharmacyclics could receive an extra $825 million on top of its $150 upfront payment, based on development and regulatory milestone payments.
The drug is currently undergoing mid-stage trials, and both firms will collaborate on its development for cancer and other possible indications.
Each company will lead development for specific indications as set out in a global development plan, with Pharmacyclics taking on 40% of the development costs and Janssen; 60 per cent.
The agreement includes plans to launch multiple Phase III trials of PCI-32765 over the next several years.
Following regulatory approval, both Pharmacyclics and Janssen will and jointly commercialise PCI-32765.
In its native US, Pharmacyclics will book sales and take a lead role in US commercial strategy development, with both firms sharing in commercialisation activities.
Outside of the country Janssen will book sales and lead and perform commercialisation activities.
Bob Duggan, chief executive of Pharmacyclics, said: “Over the past 18 months we have met a number of outstanding individuals and very high quality organisations around the world.
“In the end, we felt that Janssen was the appropriate strategic fit for us and for PCI-32765. We look forward to sharing with Janssen the responsibility and accountability for turning our vision for PCI-32765 into an everyday reality.”
Ben Adams
Related Content
Janssen’s study for nipocalimab as indicated for EOS-HDFN published in The New England Journal of Medicine
Johnson & Johnson company Janssen has announced that the results from its phase 2 trial …
GSK enters agreement for license for JNJ-3089 for development of bepirovirsen
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen …
Janssen and Sanofi enter agreement for potential vaccine programme
Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …
